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Genome editing has attracted wide interest for the
generation of cellular models of disease using human
pluripotent stem cells and other cell types. CRISPR-
CassystemsandTALENscan targetdesiredgenomic
sites with high efficiency in human cells, but recent
publications have led to concern about the extent
to which these tools may cause off-target mutagenic
effects that could potentially confound disease-
modeling studies. Using CRISPR-Cas9 and TALEN
targeted human pluripotent stem cell clones, we per-
formed whole-genome sequencing at high coverage
in order to assess the degree of mutagenesis across
the entire genome. In both types of clones, we found
that off-targetmutationsattributable to thenucleases
were very rare. From this analysis, we suggest that,
although some cell types may be at risk for off-target
mutations, the incidence of such effects in human
pluripotent stem cells may be sufficiently low and
thus not a significant concern for disease modeling
and other applications.Clustered regularly interspaced short palindromic repea
(CRISPR)-associated (Cas) systems and transcription acti-t
vator-like effector nucleases (TALENs) are recently developed
genome-editing tools that target desired genomic sites in
mammalian cells (Miller et al., 2011; Hockemeyer et al., 2011;
Cong et al., 2013; Mali et al., 2013b; Cho et al., 2013; Jinek
et al., 2013). The most commonly employed CRISPR-Cas sys-
tem, derived fromStreptococcus pyogenes, uses Cas9 nuclease
that complexes with a guide RNA that hybridizes a 20 nt DNA
sequence (protospacer) immediately preceding an NGG motif
(protospacer-associated motif or PAM), resulting in a double-
strand break (DSB) 3 bp upstream of the NGG (Jinek et al.,
2012). TALENs bind as a pair on sequences surrounding a
genomic site, positioning a dimer of FokI nuclease domains inorder to generate a DSB at the site. The introduction of a DSB
at a specified genomic site allows for modification of the site
via either nonhomologous end-joining (NHEJ), which typically in-
troduces an insertion or deletion (indel), or homology-directed
repair, which can be exploited to knock in a point mutation or
insert a desired sequence at the site.
One important application of genome-editing technology is
disease modeling (Musunuru, 2013). The ability to generate
isogenicwild-type andmutant clones for phenotypic comparison
would enable rigorous functional genetic studies. However, both
CRISPR-Cas9 and TALENs have been demonstrated to produce
off-target effects; i.e., mutagenesis at sites in the genome other
than the desired on-target site (Hockemeyer et al., 2011; Musso-
lino et al., 2011; Fu et al., 2013; Hsu et al., 2013;Mali et al., 2013a;
Pattanayak et al., 2013; Cradick et al., 2013; Cho et al., 2014).
These studies have largely focused on sites with high sequence
similarity to the on-target site and have documented mutagen-
esis rates as high as 77% for CRISPR-Cas9 and 1% for TALENs
at individual off-target sites. Relatively unexplored is whether
CRISPR-Cas9 or TALENs produce off-target effects at sites
with low sequence similarity to the on-target site. Although the
nucleasesmight have poor affinity and a low probability of gener-
ating a mutation at any given single site in the genome, they may
nonetheless generate a sizeable number of nonspecific muta-
tions across the billions of base pairs of the genome in any single
cell. This would significantly confound the validity of disease-
modeling studies that rely upon genome-edited clones.
To date, most studies of nuclease off-target effects have been
performed in aggregated pools of transformed or immortalized
cultured human cells such as human embryonic kidney 293T
and K562 cells that are not well suited for disease modeling.
Therefore, we decided to study nuclease off-target effects
generated in a ‘‘real-world’’ application of genome editing
centered on human pluripotent stem cell (hPSC) clones being
actively used for biological studies (e.g., Ding et al., 2013a).
We assessed the degree of genome-wide off-target muta-
genesis in hPSC clones targeted with either CRISPR-Cas9 or
TALENs. We performed whole-genome sequencing at high
coverage (603 target coverage) of ten cell lines, including nineCell Stem Cell 15, 27–30, July 3, 2014 ª2014 Elsevier Inc. 27
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Table 1. Numbers of Unique On-Target and Candidate Off-Target










Clones A B C D E F G H I
On-target indels — 2 2 — 1a 1a — 1 1a
On-target SVs — — — — — — — 1b —
Likely off-target indel — 1 — — — — — — —
Other candidate off-
target indels
2 1 2 4 4 2 3 5 4
Candidate off-
target SVs
— — — — — 1 — — —
SNVs 64 115 142 55 94 74 111 127 112
See also Figure S1 and Tables S1–S3.
aHomozygous for indels.
b261 bp duplicated insertion.
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et al., 2013a, 2013b) (Figure 1): the human embryonic stem cell
line HUES 9: three HUES 9 clones exposed to TALENs targeting
the SORT1 gene with one clone remaining wild-type in both
alleles (clone A) and two clones bearing indels in both SORT1
alleles (clones B and C), three HUES 9 clones exposed to
CRISPR-Cas9 targeting the same site in the SORT1 gene with
one wild-type clone (clone D) and two clones bearing indels in
both SORT1 alleles (clones E and F), and three HUES 9 clones
exposed to CRISPR-Cas9 targeting the LINC00116 gene with
one wild-type clone (clone G) and two clones bearing indels in
both LINC00116 alleles (clones H and I). All of the HUES 9 clones
were derived from the same stock of parental HUES 9 cells.
Notably, we had found the targeting efficiency of the SORT1
TALENs to be 11%, in contrast to CRISPR-Cas9 for SORT1,
which was 76%, The targeting efficiency of CRISPR-Cas9 for
LINC00116 was 57% (Ding et al., 2013b).
Upon obtaining the whole-genome sequencing data, we as-
sessed the clones for small indels, single-nucleotide variants
(SNVs), and structural variants (SVs), which include chromo-
somal inversions, rearrangements, duplications, and deletions
(Supplemental Experimental Procedures available online). We
largely focused on the identification of small indels and SVs
because they comprise virtually all of the mutations introduced
by NHEJ. After filtering for the small indels most likely to be
true positives and to be potential off-target mutations (rather
than mutations that arose in the parental cell pool) and confirma-
tion with Sanger sequencing, we identified a total of 28 such
indels across the nine experimental clones in comparison to
the parental HUES 9 cells as the reference. Notably, all of the
previously known on-target indels (seven in total) were correctly
identified by the whole-genome sequencing and filtering (TablesFigure 1. On- and Off-Target Mutations
(A) HUES 9 clones targeted in the SORT1 gene with TALENs or CRISPR-Cas9.
(B) HUES 9 clones targeted in the LINC00116 genewith CRISPR-Cas9. For TALEN
sequences. For CRISPR-Cas9 targeted clones, the boxes indicate the 20 bp se
deletions and insertions in the two alleles of each clone are indicated. For the off
indicated in bold, and the deletion in one allele of the clone is indicated.1 and S1). One of the 28 off-target indels was a frameshift in the
coding sequence of ZDHHC11 (in clone I). None of the other in-
dels lay in either the coding sequence of a gene or the expressed
sequence of an annotated noncoding RNA.
None of the indels in CRISPR-Cas9 clones were within 100 nt
of a potential off-target site as predicted by sequence similar-
ity—up to six mismatches—with the on-target site, and none
lay near sequences that matched the on-target sites better
than would be expected by chance (Figure S1). Moreover,
none of the indels lay within 100 nt of a sequence perfectly
matching the last 10 nt of the protospacer with an adjacent
PAM site (NGG as well as NAG, which has also been shown to
be tolerated) (Hsu et al., 2013; Pattanayak et al., 2013). Further-
more, we paid special attention to the indels that lay within 5 bp
upstream of a potential PAM site (Table S1), where CRISPR-
Cas9-mediated DSBs would be expected to occur. Although
the majority of indels had a potential PAM site, none of the adja-
cent sequences matched the on-target site better than would be
expected by chance (Figure S1).
Oneof the indels inaTALENclonewas locatedbetween twopo-
tential off-target binding sites as predicted by sequence similarity
with the on-target sites—one with three mismatches and another
with four mismatches—with the binding sites being 17 bp apart,
within the optimal range for generating a DSB with TALENs of
this type (Ding et al., 2013a) (Figure 1A). None of the other TALEN
clone indels were optimally positioned near a pair of degenerate
TALEN binding sites (up to five mismatches with the on-target
site), and none lay near sequences that matched the on-target
sites better than would be expected by chance (Figure S1).
None of the SVs and SNVs that passed our filtering criteria in
CRISPR-Cas9 clones was within 100 nt of a predicted off-target
site. None of the variants in TALEN clones were optimally
positioned near a pair of degenerate TALEN binding sites. We
detected 894 unique SNVs across the nine clones (average of
100 per clone) in comparison to the parental HUES 9 cell line
(Table 1). The SV analysis revealed two structural variants unique
to an individual clone: a 5.5 kb deletion on chromosome 6 in
clone F and a 261 bp segment of chromosome 4 inserted within
the LINC00116 CRISPR-Cas9 on-target site on chromosome 2
in clone H (Tables 1 and S2). Sanger sequencing confirmed
that both alleles of the chromosome 4 region were intact in
clone H, signifying a duplicated insertion into the chromosome
2 on-target site rather than a balanced translocation. We specu-
late that, because of microhomology, the chromosome 4 region
was used as a repair template for a DSB at the on-target site.
Just one of the detected variants—a TALEN clone indel—
seems certain to be a nuclease-mediated off-target effect. It is
probable that some, if not all, of the other indels and SVs reflect
clonal heterogeneity within the original stock of HUES 9 cells.
Previous studies have documented mutagenesis occurring dur-
ing the derivation and expansion of hPSCs (Hussein et al., 2011;
Gore et al., 2011; Howden et al., 2011; Yusa et al., 2011).targeted clones, the boxes indicate the TALEN on-target and off-target binding
quence matching the protospacer and the 3 bp PAM. For the on-target sites,
-target site, the mismatches with the TALEN on-target binding sequences are
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SNVs, which would not be predicted to result from NHEJ. None-
theless, with a maximum of just two to five confirmed events in
each individual clone, our results suggest that nuclease-medi-
ated off-target effects of CRISPR-Cas9 and TALENs do not
intrinsically cause a large degree of indiscriminate nonspecific
mutagenesis across the genome.
We note the limitations of this study. Even with whole-genome
sequencing at high coverage, it is likely that some variants in the
clones were not detected given the limitations of short-read
sequencing. The small number of sequenced clones targeted
at just two loci prevents generalization to all hPSC clones tar-
geted with any CRISPR-Cas9 or TALENs of any configuration
by any methodology. Furthermore, our results are not relevant
to therapeutic applications targeting up to millions of cells at a
time, where rare events may have deleterious consequences.
We do note that clonal heterogeneity may represent a more
serious obstacle to the generation of truly isogenic cell lines
than nuclease-mediated off-target effects, given that each of
our clones harbored a very small number of unique indels and
SVs (two to five) in comparison to a relatively larger number of
unique SNVs (average of 100) that likely arose spontaneously
in culture. This suggests that even if one had a genome-editing
tool in hand with perfect specificity, targeted clones would still
be likely to harbor some differences elsewhere in the genome.
Rigorous studies will require whole-genome sequencing of the
clones used for experiments to fully characterize their mutational
profiles, or they will need to include multiple clones for each
experimental condition to ensure that potential confounding by
any single mutation in a clone is minimized.
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